Anadolu Medical Center
| トルコ | オーストリア | スペイン | |
| 治療的アフェレーシス | から $1,350 | - | - |
| 血漿交換術 | から $1,200 | から $2,000 | から $1,800 |
| 選択的アフェレーシス | から $1,550 | - | - |
| 血漿交換 | から $3,900 | - | - |
| カスケードプラズマろ過 | から $1,850 | - | - |
Bookimedは治療的アフェレーシス価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで治療的アフェレーシス代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。治療的アフェレーシスで高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。治療的アフェレーシスの旅路でお一人になることはありません。
Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.
She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.
She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.
She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.
Dr. Zhang Yan Lin is a nationally recognized nephrologist with over 30 years in clinical care, teaching, and research. Dr. Zhang previously worked at the First Affiliated Hospital of Xiamen University.
Dr. Zhang took part in two NSFC projects, served as principal investigator for one Fujian Provincial NSFC project, and led two Xiamen Municipal key projects. Dr. Zhang is chief editor of one monograph and co-editor of three. Dr. Zhang has published more than 30 papers, including six in SCI journals.
Appointments: Deputy Chair of the Immunoadsorption and Cell Therapy Group of the Internal Medicine Branch of the Chinese Medical Association. Deputy Chair of the Nephrology Branch of the Asia-Pacific Academy of Medical and Biological Immunology. Standing Committee Member of the Nephrology and Dialysis Professional Committee of the China Non-Public Medical Institutions Association. Standing Committee Member of the East China Regional Nephrology Cooperation Committee.
Dr. Pazit Beckerman is a nephrologist with over 24 years of clinical practice in Israel. She specializes in chronic kidney disease (CKD), acute kidney injury (AKI), hemodialysis and peritoneal dialysis, hypertension-related kidney disease, glomerular diseases and proteinuria, electrolyte disorders, and kidney involvement in systemic diseases.
She served as Acting Director in 2020, Deputy Director from 2018 to 2020, and Senior Physician in the Department of Nephrology at Sheba Medical Center. She also heads the Israeli Dialysis Registry.
Education and training: MD, Hebrew University–Hadassah. Nephrology residency, Hadassah. Fellowship in nephrology, Sheba Medical Center. Biomedical Computational Studies, Bar-Ilan University. Postdoctoral fellowship, University of Pennsylvania.
Her research focuses on AKI, immune-related kidney complications, and chronic kidney disease. She has authored many publications. She is a member of the American Society of Nephrology and a board member of the Israeli Society of Nephrology and Hypertension.
Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.
He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.
He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.